title: Oxyradical-mediated clastogenic plasma factors in psoriasis: increase in clastogenic activity after PUVA.
abstract: Psoriasis is a common skin disorder characterized by hyperproliferation and incomplete differentiation of epidermal keratinocytes. Psoralen plus UVA (PUVA) is one of the treatments proposed for this disease. We had reported previously that exposure of regular blood cultures from healthy donors to PUVA leads to chromosomal breakage via the formation of transferable clastogenic materials, a phenomenon inhibitable by superoxide dismutase. In the present paper we show that these clastogenic factors (CF) are also formed in vivo. The CF were found in about 50% of the psoriasis patients studied (14 out of 31). In PUVA-treated psoriasis patients, the clastogenic activity of the plasma increased significantly between the first and the last (16th) exposure to PUVA. We hypothesize that CF formation in psoriasis is similar to that in other diseases accompanied by oxidative stress, in particular chronic inflammatory diseases with autoimmune reactions such as lupus erythematosus, progressive systemic sclerosis, rheumatoid arthritis and others. Increased superoxide production by phagocytes, formation of lipid peroxidation products and release of cytokines are considered to be responsible for the superoxide-stimulating and chromosome-damaging properties of patients' plasma. During PUVA therapy, superoxide generated via the interaction of psoralen with UVA may contribute to CF formation in addition to superoxide from inflammatory cells. An increased risk of cancer and leukemia is observed in diseases accompanied by CF formation. Therefore CF may contribute to the well-known risk of photocarcinogenesis by PUVA therapy. This additional risk may be preventable by antioxidants and superoxide scavengers.
authors.affiliation: Department of Dermatology, Hospital de Santa Maria, University of Lisboa, Portugal.
authors.forename: P
authors.initials: P
authors.lastname: Filipe
authors.forename: I
authors.initials: I
authors.lastname: Emerit
authors.forename: A
authors.initials: A
authors.lastname: Alaoui Youssefi
authors.forename: A
authors.initials: A
authors.lastname: Levy
authors.forename: L
authors.initials: L
authors.lastname: Cernjavski
authors.forename: J
authors.initials: J
authors.lastname: Freitas
authors.forename: J L
authors.initials: JL
authors.lastname: de Castro
mesh_terms: D000328:Adult; D002869:Chromosome Aberrations; D005260:Female; D005609:Free Radicals / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009153:Mutagens / Q000378:metabolism*; D011701:PUVA Therapy / Q000009:adverse effects*; D011565:Psoriasis / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D012307:Risk Factors; D012878:Skin Neoplasms / Q000209:etiology / Q000517:prevention & control
chemical_list: D005609:Free Radicals; D009153:Mutagens